Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 7/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16578761 | 1.00 | GSK3B (0.34) | GSK3BRAD52HTR3ALATS1HTR2C | |
| Hydrochloric Acid SCHEMBL26600152 | 0.98 | RAD52 (0.36) | GSK3BRAD52HTR3ALATS1HTR2C | |
| SCHEMBL17884787 | 0.73 | MMP2 (0.40) | GSK3BRAD52LATS1HTR2CROCK2 | |
| SCHEMBL17871510 | 0.73 | MMP2 (0.40) | GSK3BRAD52HTR3ALATS1HTR2C | |
| SCHEMBL20149920 | 0.73 | GSK3B (0.36) | GSK3BRAD52HTR3ALATS1HTR2C | |
| SCHEMBL16569672 | 0.72 | ADRB1 (0.38) | HTR2C | |
| SCHEMBL31155289 | 0.71 | KMT2A (0.40) | PIM3 | |
| Hydrochloric Acid SCHEMBL16569842 | 0.70 | ADRB1 (0.37) | HTR3AHTR2C | |
| SCHEMBL27581053 | 0.70 | GSK3B (0.39) | GSK3BLATS1HTR2CROCK2ROCK1 | |
| SCHEMBL27581051 | 0.70 | GSK3B (0.39) | GSK3BLATS1HTR2CROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | GSK3B 351/4885RAD52 2352/4885HTR3A 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.